HOOKIPA Pharma
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
350 5th Ave Fl 72 Ste 7240, New York Cit...Phone Number
(431) 890-6360Website
www.hookipapharma.comRevenue
$9.4 MillionStock Symbol
HOOKIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About HOOKIPA Pharma
HOOKIPA Pharma Inc. (NASDAQ: HOOK) was founded in 2011, and is headquartered in New York City. They are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.Explore more
HOOKIPA Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HOOKIPA Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when HOOKIPA Pharma launches new products
Check if HOOKIPA Pharma has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at HOOKIPA Pharma
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on HOOKIPA Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
HOOKIPA Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if HOOKIPA Pharma had a recent Job posting/layoffs
Check out if HOOKIPA Pharma is spiking on competitors!
Funding: Get notified immidiatlly once HOOKIPA Pharma has new funding data
Recommended Actions
Find VP level buyers at HOOKIPA Pharma
Find 2 more new buyers
Compare Similar Companies to HOOKIPA Pharma
Compare insights from companies similar to HOOKIPA Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
HOOKIPA Pharma
$9.4M
51-200
Public
$21.3M
2011
TC
Terry CoelhoExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
HOOKIPA Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
HOOKIPA Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about HOOKIPA Pharma.
HOOKIPA Pharma financials insights
Gather financial insights about HOOKIPA Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$21.3M
HOOKIPA Pharma Tech Stack
A closer look at the technologies used by HOOKIPA Pharma
See more technologies
Most Recent Scoops
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Earnings
Partnership, Funding, Business Development, Financial Systems, Financial Operations, Healthcare Operations, Medical Administration, Operations
Earnings
Funding, Financial Systems, Clinical Operations, Financial Operations, Manufacturing Operations, Operations, Risk
Earnings
Pain Point
Pain Point, Financial Planning, Clinical Operations, Operations
HOOKIPA Pharma News & Media
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase priceHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”).HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and suspGilead (GILD) to Acquire HOOK for $10 million
Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration of $10 million. Gilead Sciences Inc. (NASDAQ:GILD) commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. GILD is only purchasing HOOK’s antiviral programs, specifically the “HB-400” & “HB-500”. The company first […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HOOKIPA Pharma
Sign Up For FreeTo access detailed company insights
HOOKIPA Pharma Inc. (NASDAQ: HOOK) was founded in 2011, and is headquartered in New York City. They are a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting... Read More
